Hypertension
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Initial tests
Fasting laboratory tests
- Serum electrolytes
- Serum creatinine with eGFR
- Fasting plasma glucose
- Lipid profile
- FBC (haemoglobin)if neededHaemoglobin or haematocrit: basic test in the ESH 2023 work-up [2]; ESC 2024 lists it among the tests that screen for a secondary cause (polycythaemia) [3]. It is not in the HAS initial tests [4].
- HbA1cif neededESH 2023 pairs fasting plasma glucose with HbA1c [2]; ESC 2024 measures HbA1c only if fasting plasma glucose is raised [3]; HAS does not list it [4]. Outside NABM indications in people without diabetes: write “NR” (not reimbursable in France) [5].
- Serum urateif neededRoutine test in the ESH 2023 work-up [2]; neither HAS [4] nor ESC 2024 [3] retains it in the initial tests.
- Serum calciumif neededRetained by ESH 2023 [2] and by ESC 2024, which uses it to screen for hyperparathyroidism [3]; absent from the HAS initial tests [4]. See the page “Hypercalcaemia”.
- TSHif neededESC 2024 lists it among the tests screening for thyroid dysfunction, a secondary cause of hypertension [3]; it is not in the HAS initial tests [4] nor in the ESH 2023 list [2].
- Plasma aldosterone and renin, with aldosterone/renin ratio (if hypokalaemia, hypertension ≥ 180/110 mmHg, adrenal incidentaloma, sleep apnoea syndrome or family history of early hypertension or stroke before age 40; sampling conditions: see the "Resistant hypertension" tab)if neededThe 2016 French consensus recommends this screening in severe hypertension (≥ 180/110 mmHg), resistant hypertension, hypertension with hypokalaemia or with an adrenal incidentaloma, and looking for a familial form in young people with a family history of hypertension, stroke or hyperaldosteronism [6]. The 2025 American recommendation adds obstructive sleep apnoea syndrome and proposes considering it from 140/90 mmHg [7]; ESC 2024 considers it in every patient with confirmed hypertension [3]. The earlier French consensus does not retain obstructive sleep apnoea syndrome [6]. In the United States, the first measurement is done on treatment (except mineralocorticoid receptor antagonists) [7]; in France, antihypertensives that distort the result are stopped first [8].
Urine tests
- Urine protein:creatinine ratio (spot sample)
- Haematuria (blood testing, urine dipstick)if neededESH 2023 asks for a multiparameter urine dipstick in all patients [2] and ESC 2024 for urine tests, with a dipstick for blood and protein when kidney damage is suspected [3]; HAS retains only the search for proteinuria, whatever the method [4]. To be requested in case of proteinuria or suspected nephropathy.
- Urine albumin:creatinine ratio (ACR)if neededESH 2023 and ESC 2024 recommend it in every patient with hypertension [2,3]; HAS considers it unnecessary, except in non-proteinuric patients with diabetes [4].
Annual follow-up tests
Laboratory tests
- Serum electrolytes
- Serum creatinine with eGFR
Urine tests
- Urine protein:creatinine ratio (spot sample)
- Haematuria (blood testing, urine dipstick)if neededESH 2023 makes the urine dipstick a routine test in every patient with hypertension [2]; the HAS follow-up laboratory check looks for proteinuria, whatever the method [4]. Useful in case of proteinuria or known nephropathy.
Follow-up tests every 3 years
Fasting laboratory tests
- Serum electrolytes
- Serum creatinine with eGFR
- Fasting plasma glucose
- Lipid profile
Urine tests
- Urine protein:creatinine ratio (spot sample)
- Haematuria (blood testing, urine dipstick)if neededESH 2023 makes the urine dipstick a routine test in every patient with hypertension [2]; the HAS follow-up laboratory check looks for proteinuria, whatever the method [4]. Useful in case of proteinuria or known nephropathy.
Tests for resistant hypertension
Laboratory tests
- Plasma aldosterone/renin ratio
- Dexamethasone suppression test for cortisol measurement
24-hour urine collection
- Urinary metanephrines
- 24-hour urinary free cortisol
Hypertension before age 40
Fasting laboratory tests, in the morning
- Serum electrolytes
- Serum creatinine with eGFR
- Fasting plasma glucose
- Lipid profile
- FBC
- Serum calcium
- TSH
- Plasma aldosterone and renin, with aldosterone/renin ratio (sampling conditions: see the note)
Urine tests
- Urine protein:creatinine ratio (spot sample)
- Haematuria (blood testing)
- 24-hour urinary sodium (checks the normal-sodium diet at the time of the renin-aldosterone assay)
Depending on the clinical picture
- 24-hour urinary metanephrines (if episodes of headache, sweating, palpitations)if neededEpisodes of headache, sweating, palpitations: phaeochromocytoma is one of the main causes of secondary hypertension, and measurement of urinary metanephrines and normetanephrines is among the investigations of secondary hypertension [4].
- 24-hour urinary free cortisol or overnight dexamethasone suppression test (if signs of hypercortisolism)if neededSigns of hypercortisolism: Cushing's syndrome is one of the main causes of secondary hypertension; measure urinary free cortisol or plasma cortisol after a dexamethasone test [4]. See the page “Cushing's syndrome”.
- PTHif needednon-French guidelineHypercalcaemia in the tests: the serum calcium of the baseline tests is used to screen for hyperparathyroidism [3]; see the page “Hypercalcaemia”.
- Serum phosphateif needednon-French guidelineHypercalcaemia in the tests: the serum calcium of the baseline tests is used to screen for hyperparathyroidism [3]; see the page “Hypercalcaemia”.
BP ≥ 180/110 mmHg: hypertensive emergency or severe hypertension without organ damage
- Acute organ damage (chest pain, dyspnoea, neurological deficit, confusion, seizures, visual disturbance, pregnancy): no tests in the community, refer to the emergency department.
- Without acute organ damage: no hospital admission; tests from the "Initial tests" tab without delay, and specialist opinion (search for secondary hypertension).
Hypertension in children and adolescents: initial tests
Laboratory tests
- Serum electrolytes (potassium)
- Serum creatinine (GFR by the 2009 Schwartz formula)
- ASTif neededOverweight or obese child (BMI > 95th percentile) or family history of dyslipidaemia [12].
- ALTif neededOverweight or obese child (BMI > 95th percentile) or family history of dyslipidaemia [12].
- Fasting lipid profile (same context)if neededOverweight or obese child (BMI > 95th percentile) or family history of dyslipidaemia [12].
- Fasting plasma glucose (same context)if neededOverweight or obese child (BMI > 95th percentile) or family history of dyslipidaemia [12].
Urine tests (first morning urine)
- Urine sediment with red cell count (haematuria)
- Urine protein:creatinine ratio (spot sample)
Sources (15)
- L'hypertension artérielle en France : prévalence, traitement et contrôle en 2015 et évolutions depuis 2006
- Recommandations de la société européenne d'HTA (2023)
- McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J 2024;45(38):3912-4018.
- Haute Autorité de santé, Société française d’hypertension artérielle. Prise en charge de l’hypertension artérielle de l’adulte. Fiche mémo, septembre 2016.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : acte 1577 (HbA1c).
- Baguet JP, Steichen O, Mounier-Véhier C, Gosse P. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 1: Epidemiology of PA, who should be screened for sporadic PA? Ann Endocrinol (Paris) 2016;77(3):187-91.
- Cameron NA, Jones DW, Khan SS, Lloyd-Jones DM. Case-Based Applications of the 2025 AHA/ACC/Multispecialty High Blood Pressure Guideline. Hypertension. 2025;82(12):2055-2063 (article des auteurs de la recommandation AHA/ACC 2025, qui en reprend les recommandations et leurs niveaux de preuve).
- Consensus SFE/SFHTA/AFCE sur l’hyperaldostéronisme primaire, partie 2 : premières étapes diagnostiques (version française, SFHTA, 2016).
- National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline NG136, publiée le 28 août 2019, mise à jour le 26 février 2026 : recommandations 1.3.3, 1.4.46 à 1.4.52 et revue annuelle.
- Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale VersorgungsLeitlinie Hypertonie, version longue, version 1.0, 2023 (AWMF-Register-Nr. nvl-009).
- Goupil R, Tsuyuki RT, Santesso N, et al. Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care. CMAJ 2025;197(20):E549-E564. doi:10.1503/cmaj.241770
- Bouhanick B, Sosner P, Brochard K, Mounier-Véhier C, Plu-Bureau G, Hascoet S, et al. Hypertension in children and adolescents: a position statement from a panel of multidisciplinary experts coordinated by the French Society of Hypertension. Front Pediatr 2021;9:680803.
- Collège national des pédiatres universitaires (CNPU). Référentiel de pédiatrie, chapitre 50 : Hypertension artérielle.
- Prise en charge de l’hypertension artérielle de l’adulte
- Douillard C, Houillier P, Nussberger J, Girerd X. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 2: first diagnostic steps. Ann Endocrinol (Paris) 2016;77(3):192-201.